SilverJ., Bar SelaS., and Naveh-ManyT.Regulation of parathyroid cell proliferation. Curr Op Nephrol Hyperten1997; 6: 321–26.
5.
CozzolinoM., DussoA., SlatopolskyE.Role of calcium x phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol2001; 12: 2511–6.
6.
CozzolinoM., BrancaccioD., GallieniM., andE.Slatopolsky. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int2005; 68: 429–36.
7.
CozzolinoM., GallieniM., BrancaccioD.Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. J Nephrol2006; 19: 566–57.
8.
CozzolinoM., BrancaccioD., GallieniM.Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol2005; 18(1): 5–8.
9.
BrownE.M., GambaG., RiccardiD.Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature1993; 366: 575–80.
SilverJ., KilavR., Naveh-ManyT.Mechanisms of secondary hyperparathyroidism. Am J Physiol Ren Physiol2002; 283: F367–76.
12.
GaneshS.K., StackA.G., LevinN.W.Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol2001; 12: 2131–8.
13.
MarcoM.P., CraverL., BertriuA.Higher impact of mineral metabolism on cardiovascular mortality in an European hemodialysis population. Kidney Int2003; 63(suppl 85): S111–4.
14.
BlockG.A., KlassenP.S., LazarusJ.M.Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol2004; 15(8): 2208–18.
15.
WangA.Y., WangM., WooJ.Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol2003; 14: 159–68.
16.
National Kidney Foundation DOQI: Clinical Pratical Guidelines For Bone Metabolism and Disease in Chronic Kidney Diseases. Am J Kidney Dis2003; 42(4), (Suppl 3).
17.
MazzaferroS., CozzolinoM., MarangellaM.Calcimimetics, phosphate binders, vitamin D and its analouges for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology. G Ital Nefrol2007; 24(suppl 37): S107–24.
18.
KawataT., ImanishiY., KobayashiK.Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol2005; 153(4): 587–94.
19.
BlockG., KevinJ.M., De FranciscoA.L.M.Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med2004; 350: 627–35.
20.
LindbergJ.S., CulletonB., WongG.Cinacalcet HCL, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A Randomized Double-Bind, Multicenter Study. J Am Soc Nephrol2005; 16: 800–07.
21.
MoeS.M., ChertowG.M., CoburnJ.W.Achieving NKF-K/DOQI TM bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int2005; 67: 760–71.
22.
CunninghamJ., DaneseM., OlsonK., KlassenP., ChertowG.M.Effect of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int2005; 68: 1793–800.
BellowsC.G., ReimersS.M., HeerscheJ.N.Expression of mRNAs for type I collagen, bone sialoprotein, osteo-calcin and osteopontin at different stages of osteoblastic differentation and their regulation by 1,25 dihydroxyvitamin D. Cell Tissue Res1999; 297: 249–59.
25.
SjodenG., LindgrenJ.U., DeLucaH.F.Antirachitic activity of 1 alpha-hydroxyergocholecalciferol and 1 alpha-hydroxycholecalciferol in rats. J Nutr1984; 114: 2043–6.
26.
BrownA.J., FinchJ., GrieffM.The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology1993; 133: 1158–64.
27.
SlatopolskyE., CozzolinoM., FinchJ.L.Differential effects of 19-nor-1,25-(OH)2D2 and 1alpha-hydroxyvitamin D2 on calcium and phosphorum in normal and uremic rats. Kidney Int2002; 62(4): 1277–84.
28.
MartinK., GonzalezE.A., GellensM.19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol1998; 9(8): 1427–32.
29.
SpragueS.M., LlachF., AmdahlM.Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int2003; 63(4): 1483–90.
30.
TengM., WolfM., LowrieE.Survival of patients undergoing hemodialysis with paricalcitol or calcitriol. N Engl J Med2003; 349: 446–56.
31.
TengM., WolfM., OfsthunM.N.Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol2005; 16: 1115–25.
